Edition:
United States

Evogene Ltd (EVGN.OQ)

EVGN.OQ on NASDAQ Stock Exchange Global Market

3.47USD
9:48am EST
Change (% chg)

$0.10 (+2.97%)
Prev Close
$3.37
Open
$3.40
Day's High
$3.47
Day's Low
$3.40
Volume
1,921
Avg. Vol
2,021
52-wk High
$5.76
52-wk Low
$3.37

Latest Key Developments (Source: Significant Developments)

Evogene Q3 loss per share $0.20
Wednesday, 22 Nov 2017 07:00am EST 

Nov 22 (Reuters) - Evogene Ltd ::Evogene reports third quarter 2017 financial results.Q3 revenue $700,000 versus $1.5 million.Evogene Ltd - ‍in 2018, Evogene expects net cash usage of $14 million to $16 million.Evogene Ltd qtrly loss per share $0.20​.  Full Article

Evogene says co, Rahan Meristem announce positive results in 2nd year field trials
Tuesday, 26 Sep 2017 07:00am EDT 

Sept 26 (Reuters) - Evogene Ltd ::Evogene- Co, Rahan Meristem announce positive results in 2nd year field trials addressing Black Sigatoka disease in banana,utilization of results for genome editing​.Evogene Ltd - ‍parties also announced their agreement to utilize revolutionary genome editing technology​.  Full Article

Evogene posts Q2 ‍loss per share $0.18​
Thursday, 10 Aug 2017 07:30am EDT 

Aug 10 (Reuters) - Evogene Ltd :Evogene reports second quarter 2017 financial results.Q2 revenue $1.2 million versus $1.8 million.‍Total revenues for Q2 of 2017 were $1.2 million, compared to $1.8 million for Q2 in 2016​.‍Continues to expect that its net cash usage for full-year 2017 will be in range of $16 to $18 million​.Qtrly ‍loss per share $0.18​.  Full Article

Evogene ltd - entered into a multiyear collaboration with DuPont Pioneer
Wednesday, 26 Jul 2017 07:00am EDT 

July 26 (Reuters) - E I Du Pont De Nemours And Co :Evogene Ltd - entered into a multiyear collaboration with DuPont Pioneer.Evogene Ltd - under terms of agreement, DuPont will provide access to its extensive seed treatment application technology and product development expertise.Evogene Ltd - scope of agreement includes research and development of microbiome-based seed treatments in corn.  Full Article

Evogene Ltd reaches an important milestone in its crop disease collaboration with Monsanto Company​
Tuesday, 11 Jul 2017 07:00am EDT 

July 11 (Reuters) - Evogene Ltd ::Evogene Ltd- ‍company reached an important milestone in its crop disease collaboration with Monsanto Company​.Evogene - announced completion of candidate gene discovery stage in co's yield and abiotic stress collaboration, which mainly focuses on corn and soy.Evogene - collaboration will now focus on progressing selected gene candidates through additional testing in Monsanto's product development pipeline.Evogene Ltd- ‍demonstration of positive fusarium resistance results with Evogene discovered genes​.  Full Article

Evogene announces positive results in insect control seed trait program
Tuesday, 20 Jun 2017 07:00am EDT 

June 20 (Reuters) - Evogene Ltd ::Evogene Ltd announces positive results in insect control seed trait program and advancement to Phase-I of First Toxin against Western Corn Rootworm.Evogene Ltd says is advancing into Phase-I A gene, EVO30495, displaying high potency against Western Corn Rootworm, which is a major pest in corn.Evogene -EVO30495 has met all of phase advancement criteria, including efficacy and initial estimation of lower risk of toxicity to other organisms.  Full Article

Evogene reports Q1 loss per share $0.19
Wednesday, 17 May 2017 07:04am EDT 

May 17 (Reuters) - Evogene Ltd :Evogene reports first quarter 2017 financial results.Q1 revenue $700,000 versus $2.0 million.Evogene Ltd - continues to expect that its net cash usage for full-year 2017 will be in range of $16 to $18 million.Evogene Ltd - by end of quarter, there has been an about 8 percent net reduction in total headcount for co since year end 2016.Qtrly loss per share $0.19.Evogene ltd - "as we look forward", expect decline in revenues to continue.  Full Article

Evogene Q4 revenue $1.2 million
Monday, 27 Feb 2017 07:03am EST 

Evogene Ltd : Evogene reports fourth quarter and full year 2016 financial results . Q4 revenue $1.2 million versus $2.5 million . Evogene ltd - company estimates that its net cash usage for full year 2017 will be in range of $16 to $18 million .Evogene Ltd - net loss for Q4 of 2016 was $6.6 million compared with a net loss of $5.5 million for same period in 2015.  Full Article

Evogene, ICL Innovation enter multi-year R&D collaboration
Tuesday, 14 Feb 2017 07:00am EST 

Evogene Ltd :Evogene Ltd - co, ICL Innovation entered a multi-year research and development collaboration for discovery of novel crop enhancers.  Full Article

Migdal Insurance & Financial Holdings Ltd reports a 7.68 percent passive stake in Evogene Ltd as of Dec 31, 2016 - SEC filing
Monday, 30 Jan 2017 06:09am EST 

Evogene Ltd :Migdal Insurance & Financial Holdings Ltd reports a 7.68 percent passive stake in Evogene Ltd as of Dec 31, 2016 - SEC filing.  Full Article

BRIEF-Evogene Q3 loss per share $0.20

* Evogene Ltd - ‍in 2018, Evogene expects net cash usage of $14 million to $16 million